ATE285781T1 - Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat - Google Patents

Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat

Info

Publication number
ATE285781T1
ATE285781T1 AT00946170T AT00946170T ATE285781T1 AT E285781 T1 ATE285781 T1 AT E285781T1 AT 00946170 T AT00946170 T AT 00946170T AT 00946170 T AT00946170 T AT 00946170T AT E285781 T1 ATE285781 T1 AT E285781T1
Authority
AT
Austria
Prior art keywords
angiogenesis
treatment
sulphate
dextrine
dependent diseases
Prior art date
Application number
AT00946170T
Other languages
English (en)
Inventor
Sunil Shaunak
Original Assignee
Ml Lab Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ml Lab Plc filed Critical Ml Lab Plc
Application granted granted Critical
Publication of ATE285781T1 publication Critical patent/ATE285781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AT00946170T 1999-07-22 2000-07-24 Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat ATE285781T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917092.0A GB9917092D0 (en) 1999-07-22 1999-07-22 Treatment of angiogenesis-dependent conditions
PCT/GB2000/002799 WO2001007057A1 (en) 1999-07-22 2000-07-24 Treatment of angiogenesis dependent conditions with dextrin sulphate

Publications (1)

Publication Number Publication Date
ATE285781T1 true ATE285781T1 (de) 2005-01-15

Family

ID=10857651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946170T ATE285781T1 (de) 1999-07-22 2000-07-24 Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat

Country Status (15)

Country Link
US (1) US6689764B1 (de)
EP (1) EP1196180B1 (de)
JP (1) JP2003505423A (de)
AT (1) ATE285781T1 (de)
AU (1) AU6004300A (de)
CA (1) CA2378395A1 (de)
DE (1) DE60017136T2 (de)
ES (1) ES2234635T3 (de)
GB (1) GB9917092D0 (de)
HK (1) HK1044112B (de)
IL (1) IL146828A0 (de)
MX (1) MXPA02000755A (de)
NO (1) NO20020313L (de)
PL (1) PL353860A1 (de)
WO (1) WO2001007057A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102559D0 (en) * 2001-02-01 2001-03-21 Ml Lab Plc Treatment for angiogenesis-dependant condition
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
JP2013521300A (ja) * 2010-03-03 2013-06-10 ネオキュティス エスアー 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法
ES2777836T3 (es) 2017-05-17 2020-08-06 Tx Medic Ab Tratamiento del glaucoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61758B1 (en) 1986-05-23 1994-11-30 Daiichi Seiyaku Co Use of a sulfated polysaccharide
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
GB9625193D0 (en) 1996-12-04 1997-01-22 Ml Lab Plc Treatment of highly vascular tumours

Also Published As

Publication number Publication date
PL353860A1 (en) 2003-12-01
EP1196180A1 (de) 2002-04-17
JP2003505423A (ja) 2003-02-12
AU6004300A (en) 2001-02-13
IL146828A0 (en) 2002-07-25
DE60017136D1 (de) 2005-02-03
WO2001007057A1 (en) 2001-02-01
HK1044112B (en) 2005-07-15
DE60017136T2 (de) 2006-03-30
HK1044112A1 (en) 2002-10-11
NO20020313D0 (no) 2002-01-21
EP1196180B1 (de) 2004-12-29
US6689764B1 (en) 2004-02-10
GB9917092D0 (en) 1999-09-22
NO20020313L (no) 2002-02-20
ES2234635T3 (es) 2005-07-01
CA2378395A1 (en) 2001-02-01
MXPA02000755A (es) 2002-07-22

Similar Documents

Publication Publication Date Title
DE60037578D1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
ATE357272T1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
ES2192839T3 (es) Timosina beta 4 oxidada.
FI923158A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoidossa
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
BR0014381A (pt) Derivados de 5-beta-sapogenina e pseudossapogenina e seu uso no tratamento de demência
NO991619D0 (no) Anvendelse av en H+, K+-ATPase-inhibitor i behandlingen av nesepolypper
DK1220852T3 (da) Substituerede diazepaner
DE60017136D1 (de) Behandlung von angiogenese-abhängigen erkrankungen mit dextrinsulphat
NO20015673L (no) IL6RIL6 kimaere for behandlingen av nevrodegenerative sykdommer
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
DE60003074D1 (de) Fusidinsäure-derivate
DE60016762D1 (de) Behandlung von allergischer rhinitis mit bestimmten vasoaktiven aminbindenden proteinen
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ATE390144T1 (de) Behandlung von fibrosen
NO20030762D0 (no) Forbedret spesifisitet i behandling av sykdommer
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
DE59809592D1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties